ModernMedicine Resource Center More Topics

Targeted Therapy Resource Center

What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
A new castration-resistant prostate cancer entity?Urology Times SUO internship program member Brandon Manley, MD, reports on an SUO presentation highlighting several interesting findings on advanced prostate cancer with variant histology.
  • 1
  • 2